Ltbp complex-specific inhibitors of tgf-beta 1 and uses thereof
US-2020231682-A1 · Jul 23, 2020 · US
LTBP complex-specific inhibitors of TGFβ and uses thereof
US11214614B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11214614-B2 |
| Application number | US-202016997438-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 19, 2020 |
| Priority date | Jan 30, 2019 |
| Publication date | Jan 4, 2022 |
| Grant date | Jan 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ activation, and treating subjects suffering from TGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ inhibitor for a subject in need thereof are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody, or an antigen-binding fragment thereof, that specifically binds a human LTBP1-proTGFβ complex and a human LTBP3-proTGFβ complex, comprising a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 318 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 319. 2. The antibody, or antigen-binding fragment thereof, of claim 1 , wherein the heavy chain variable domain consists of the amino acid sequence of SEQ ID NO: 318 and the light chain variable domain consists of the amino acid sequence of SEQ ID NO: 319. 3. A pharmaceutical composition comprising the antibody, or the antigen-binding fragment thereof, of claim 1 or claim 2 .
Assignees
Inventors
Classifications
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title
Complementarity determining region [CDR] · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11214614B2 cover?
- Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ activation, and treating subjects suffering from TGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent…
- Who is the assignee on this patent?
- Scholar Rock Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).